108_CD Alliance_NNP UniChem_NNP Plc_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD 47_CD RELATED_VBN PARTY_NN DISCLOSURES_NNS CONTINUED_VBD Key_NNP management_NN remuneration_NN The_DT remuneration_NN of_IN the_DT executive_NN Directors_NNS ,_, who_WP are_VBP the_DT key_JJ management_NN personnel_NNS of_IN the_DT Group_NNP ,_, is_VBZ set_VBN out_RP below_IN in_IN aggregate_NN for_IN each_DT of_IN the_DT categories_NNS specified_VBN by_IN IAS_NNP 24_CD Related_NNP Party_NNP Disclosures_NNS ._.
Further_JJ information_NN regarding_VBG the_DT individual_JJ remuneration_NN of_IN individual_JJ Directors_NNS is_VBZ provided_VBN in_IN the_DT Board_NNP report_NN on_IN remuneration_NN ._.
2005_CD 2004_CD million_CD million_CD Short-term_JJ employee_NN benefits_NNS 3.8_CD 3.7_CD Post-employment_NN benefits_NNS 1.1_CD 0.6_CD Other_JJ long-term_JJ benefits_NNS Termination_NN benefits_NNS 0.5_CD 0.8_CD Share-based_JJ compensation_NN charge_NN 2.1_CD 0.8_CD 7.5_CD 5.9_CD 48_CD CONTINGENT_NNP LIABILITIES_NNP The_NNP Group_NNP offers_VBZ its_PRP$ UK_NNP wholesale_JJ customers_NNS access_NN to_TO long-term_JJ financing_NN for_IN their_PRP$ pharmacy_NN businesses_NNS through_IN financing_VBG arrangements_NNS developed_VBN by_IN the_DT Group_NNP with_IN its_PRP$ banks_NNS ._.
The_DT Company_NN supports_VBZ these_DT arrangements_NNS through_IN the_DT provision_NN of_IN guarantees_NNS ,_, which_WDT at_IN 31_CD December_NNP 2005_CD amounted_VBD to_TO 19.6_CD million_CD 2004_CD 18.6_CD million_CD ._.
The_DT Group_NNP has_VBZ written_VBN a_DT number_NN of_IN guarantees_NNS in_IN relation_NN to_TO third_JJ party_NN funding_NN arrangements_NNS with_IN subsidiaries_NNS ._.
These_DT guarantees_NNS can_MD only_RB be_VB exercised_VBN by_IN the_DT lender_NN in_IN the_DT event_NN of_IN predefined_JJ events_NNS all_DT of_IN which_WDT reflect_VBP financial_JJ risks_NNS ._.
Therefore_RB these_DT agreements_NNS are_VBP accounted_VBN for_IN under_IN IAS_NNP 37_CD ._.
Guarantees_NNS are_VBP also_RB provided_VBN by_IN another_DT Group_NNP company_NN that_WDT totalled_VBD 11.3_CD million_CD at_IN 31_CD December_NNP 2005_CD 2004_CD 30.7_CD million_CD ._.
Total_JJ loans_NNS outstanding_JJ through_IN these_DT financing_VBG arrangements_NNS at_IN 31_CD December_NNP 2005_CD were_VBD 205.6_CD million_CD 2004_CD 205.8_CD million_CD ._.
On_IN 31_CD December_NNP 2005_CD the_DT total_JJ extent_NN of_IN these_DT guarantees_NNS amounted_VBD to_TO 30.9_CD million_CD 2004_CD 49.3_CD million_CD ._.
In_IN the_DT last_JJ five_CD years_NNS the_DT Group_NNP has_VBZ not_RB suffered_VBN any_DT loss_NN in_IN relation_NN to_TO these_DT schemes_NNS ._.
49_CD POST_NN BALANCE_NN SHEET_NN EVENTS_NNS On_IN 17_CD February_NNP 2006_CD the_DT Group_NNP announced_VBD that_IN it_PRP had_VBD reached_VBN an_DT agreement_NN to_TO enter_VB the_DT Russian_JJ pharmaceutical_JJ wholesale_JJ market_NN through_IN the_DT acquisition_NN of_IN a_DT 96_CD %_NN controlling_VBG stake_NN in_IN A._NN P._NNP Apteka_NNP Holding_NNP Limited_NNP ,_, the_DT parent_NN company_NN of_IN Apteka_NNP Holding_NNP ZAO_NNP ,_, for_IN a_DT consideration_NN of_IN approximately_RB 18_CD million_CD ._.
In_IN addition_NN the_DT Group_NNP will_MD assume_VB approximately_RB 10_CD million_CD of_IN net_JJ debt_NN ._.
The_DT Group_NNP will_MD have_VB an_DT option_NN to_TO acquire_VB the_DT remaining_VBG 4_CD %_NN of_IN A._NN P._NNP Apteka_NNP Holding_NNP Limited_NNP within_IN three_CD to_TO six_CD years_NNS ._.
The_DT transaction_NN ,_, which_WDT is_VBZ conditional_JJ upon_IN receiving_VBG regulatory_JJ approval_NN ,_, is_VBZ expected_VBN to_TO be_VB completed_VBN by_IN the_DT end_NN of_IN March_NNP 2006_CD ._.
50_CD TRANSITION_NNP TO_TO IFRS_NNP All_NNP references_NNS to_TO UK_NNP GAAP_NNP in_IN this_DT note_NN are_VBP to_TO UK_NNP GAAP_NNP applicable_JJ for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD ._.
This_DT is_VBZ the_DT first_JJ year_NN that_IN the_DT Group_NNP has_VBZ presented_VBN its_PRP$ financial_JJ statements_NNS under_IN IFRS_NNP ._.
The_DT last_JJ financial_JJ statements_NNS under_IN UK_NNP GAAP_NNP were_VBD for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD and_CC the_DT date_NN of_IN transition_NN to_TO IFRS_NNP was_VBD 1_CD January_NNP 2004_CD ._.
On_IN 18_CD July_NNP 2005_CD ,_, the_DT Group_NNP published_VBD detailed_JJ income_NN statement_NN and_CC balance_NN sheet_NN reconciliations_NNS of_IN UK_NNP GAAP_NNP to_TO IFRS_NNP ._.
The_DT following_NN is_VBZ an_DT abridged_JJ extract_VB of_IN the_DT published_VBN document_NN describing_VBG the_DT effects_NNS of_IN adoption_NN of_IN IFRS_NNP and_CC the_DT reconciliations_NNS required_VBN in_IN the_DT year_NN of_IN transition_NN ._.
Summary_NN of_IN the_DT effects_NNS of_IN IFRS_NNP adoption_NN The_DT principal_JJ impacts_NNS of_IN IFRS_NNP on_IN the_DT Groups_NNS 2004_CD financial_JJ statements_NNS were_VBD as_IN follows_VBZ :_: recognition_NN of_IN a_DT charge_NN for_IN the_DT fair_JJ value_NN of_IN share-based_JJ compensation_NN :_: requirement_NN not_RB to_TO amortise_VB goodwill_NN :_: recognition_NN of_IN deferred_VBN taxation_NN liabilities_NNS on_IN pharmacy_NN licences_NNS ,_, unremitted_JJ earnings_NNS of_IN associates_NNS and_CC rolled_VBD over_IN capital_NN gains_NNS :_: and_CC recognition_NN of_IN dividends_NNS only_RB when_WRB they_PRP are_VBP declared_VBN rather_RB than_IN when_WRB proposed_VBN ._.
In_IN terms_NNS of_IN the_DT 2004_CD results_NNS ,_, reported_VBD profits_NNS increased_VBN under_IN IFRS_NNP ,_, mainly_RB because_IN of_IN the_DT reversal_NN of_IN goodwill_NN amortisation_NN and_CC the_DT reversal_NN of_IN goodwill_NN recycled_VBN from_IN reserves_NNS on_IN the_DT disposal_NN of_IN subsidiaries_NNS ._.
Impact_NN on_IN profit_NN Excluding_VBG goodwill_NN amortisation_NN ,_, the_DT profit_NN on_IN disposal_NN of_IN subsidiaries_NNS and_CC amounts_NNS written_VBN off_RP investments_NNS ,_, the_DT effect_NN of_IN adoption_NN of_IN IFRS_NNP was_VBD not_RB significant_JJ ._.
The_DT Group_NNP considers_VBZ the_DT measurement_NN of_IN profit_NN excluding_VBG these_DT items_NNS to_TO be_VB a_DT useful_JJ indication_NN of_IN underlying_VBG performance_NN ._.
The_DT reduction_NN in_IN profits_NNS as_IN a_DT result_NN of_IN the_DT requirement_NN to_TO recognize_VB a_DT charge_NN for_IN the_DT fair_JJ value_NN of_IN share-based_JJ compensation_NN awards_NNS was_VBD largely_RB offset_VBN by_IN the_DT net_JJ credit_NN arising_VBG from_IN the_DT movements_NNS in_IN deferred_JJ taxation_NN liabilities_NNS recognized_VBN on_IN unremitted_JJ earnings_NNS of_IN associates_NNS ,_, pharmacy_NN licences_NNS and_CC rolled_VBD over_IN capital_NN gains_NNS ._.
Impact_NN on_IN net_JJ assets_NNS Net_JJ assets_NNS at_IN 31_CD December_NNP 2004_CD decreased_VBN under_IN IFRS_NNP ._.
This_DT was_VBD predominantly_RB due_JJ to_TO the_DT recognition_NN of_IN additional_JJ deferred_VBN taxation_NN liabilities_NNS under_IN IFRS_NNP as_IN a_DT general_JJ principle_NN ,_, the_DT recognition_NN of_IN deferred_VBN taxation_NN liabilities_NNS is_VBZ more_RBR comprehensive_JJ under_IN IFRS_NNP than_IN UK_NNP GAAP_NNP ._.
Partially_RB offsetting_VBG this_DT reduction_NN in_IN net_JJ assets_NNS was_VBD the_DT reversal_NN of_IN the_DT 2004_CD goodwill_NN amortisation_NN charge_NN and_CC the_DT accrual_NN for_IN the_DT proposed_VBN 2004_CD final_JJ dividend_NN ._.
